Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Advances in Therapy is Scopus-indexed (Q1, CiteScore 7.6), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Adis.
Checked against the index lists dated .
ISSN 0741-238XVerify ISSN ↗1865-8652Verify ISSN ↗
Publisher: Adis
Cost to publish: About US$4,790 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 46 / 278 | 83rd | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1984–present, best quartile Q1, CiteScore 7.6.
Advances in Therapy is Q1 in Pharmacology (medical) (rank 46 of 278), by CiteScore 2025.
Advances in Therapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 7.6, which places it in quartile Q1 at the 83rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.418, quartile Q1, with an H-index of 99.
The publisher lists an article processing charge of about US$4,790 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Advances in Therapy is published by Adis. Its print ISSN is 0741-238X and its online ISSN is 1865-8652.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Advances in Therapy has an h-index of 115 and a 2-year mean of 4.14 citations per paper (OpenAlex). Its Scopus CiteScore is 7.6, quartile Q1. On 2-year citations it ranks #44 of 271 Scopus journals in Pharmacology (medical).
Advances in Therapy published 369 papers in 2025; its busiest recent year was 2021 with 401. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2026), authors are most often from United States (30.8%), China (13.4%) and Japan (8%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.